← All Macrogenics INC filings

Macrogenics INC 8-K filings

NASDAQ
MGNX
Macrogenics INC
8-K: MacroGenics Reports 2023 Financial Results and Provides Corporate Update, Highlighting Pipeline Advancements
MacroGenics announced its 2023 financial results and provided an update on its clinical pipeline, including the completion of enrollment in the TAMARACK Phase 2 study and the initiation of a Phase 1 study for MGC026.